Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 20 de 292 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Cortese S. Psychosis during attention deficit–hyperactivity disorder treatment with stimulants. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103068]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103067]
3.Enlace a cita original Cita con resumen
Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, Rodriguez V, Jongsma HE, Ferraro L, La Cascia C, La Barbera D, Tarricone I, Berardi D, Szöke A, Arango C, Tortelli A, Velthorst E, Bernardo M, Del-Ben CM, Menezes PR, Selten J-P, Jones PB, Kirkbride JB, Rutten BPF, de Haan L, Sham PC, Van Os J, Lewis CM, Lynskey M, Morgan C, Murray R, FRS the EU-GEI WP2 Group. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry 2019:19 de marzo. [Ref.ID 103060]
4. Cita con resumen
Costa CS, Bagatin E, Martimbianco ALC, da Silva EMK, Lúcio MM, Magin P, Riera R. Oral isotretinoin for acne. Cochrane Database of Systematic Reviews 2018:24 de noviembre. [Ref.ID 102889]
5. Cita con resumen
Anónimo. Hallucinations and pimavanserin (NUPLAZID), a new kind of drug for psychosis. ISMP Quarter Watch 2018:6. [Ref.ID 102509]
6. Cita con resumen
Jongsma HE, Gayer-Anderson C, Lasalvia A, Quattrone D, Mulé A, Szoke A, Selten J-P, Turner C, Arango C, Tamcone I, Berardt D, Tortelli A, Llorca P-M, de Haan L, Bobes J, Bernardo M, Sanjuán J, Santos JL, Arrojo M, Del-Ben CM, Menezes PR, Murray RM, Rutten BP, Jones PB, Van Os J, Morgan C, Kirkbride JB, for the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 2 (EU-GEI WP2) Group. Treated incidence of psychotic disorders in the multinational EU-GEI study. JAMA Psychiatry 2017:6 de diciembre. [Ref.ID 102177]
7.Tiene citas relacionadas Cita con resumen
Öngür D. Dopamine dysfunction in schizophrenia and bipolar disorder - Never the twain shall meet?. JAMA Psychiatry 2017:11 de octubre. [Ref.ID 102090]
8.Tiene citas relacionadas Cita con resumen
Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M, Turkheimer F, McGuire P, Young AH, Howes OD. A tests of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry 2017:11 de octubre. [Ref.ID 102089]
9. Cita con resumen
Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]
10. Cita con resumen
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]
11. Cita con resumen
Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Affairs 2017;36:1 de mayo. [Ref.ID 101570]
12. Cita con resumen
Németh G, Laszlovsky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy A, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet 2017;389:1103-13. [Ref.ID 101497]
13. Cita con resumen
Patel AN, Lee S, Andrews HF, Pelton GH, Schultz SK, Sultzer DL, Mintzer J, de la Pena D, Gupta S, Colon S, Schimming C, Levin B, Devanand DP. Prediction of relapse after discontinuation of antipsychotic treatment in Alzheimer’s disease: the role of hallucinations. Am J Psychiatry 2016:1. [Ref.ID 100993]
14. Cita con resumen
Anónimo. Drugs for bipolar disorder. Med Lett Drugs Ther 2016;58:103-6. [Ref.ID 100682]
15. Cita con resumen
Stergiakouli E, Thapar A, Smith GD. Association of acetaminophen use during pregnancy with behavioral problems in childhood. Evidence against confounding. JAMA Intern Med 2016:15 de agosto. [Ref.ID 100580]
16. Cita con resumen
Anónimo. Cannabis and cannabinoids. Med Lett Drugs Ther 2016;58:97-8. [Ref.ID 100510]
17. Cita con resumen
Anónimo. Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther 2016;58:74-5. [Ref.ID 100456]
19. Cita con resumen
Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, Stewart R, McGuire P, Bhattacharyya S. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study . BMJ Open 2016;6:e009888. [Ref.ID 100279]
20.Enlace a cita original Cita con resumen
Anónimo. FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease. U.S. Food and Drug Administration 2016:29 de abril. [Ref.ID 100215]
Seleccionar todas
 
 1 a 20 de 292 siguiente >>